24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profileOngoing registrational…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Key insights of study conducted by Insurance Awareness Committee (IAC-Life) and IMRB Kantar for Telangana are as follows: 100% awareness…
MANILA, Philippines, July 25, 2025 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") is strengthening its long-term…
NEW DELHI, July 14, 2025 /PRNewswire/ -- HSG Laser, a global leader in intelligent laser cutting and automation technology, will…
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show that PALSONIFY was well tolerated and IGF-1 levels…
ROLLER's purpose is to help create experiences that bring joy and happiness to the world. They achieve this by empowering…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…
June 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to…
